These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience. Sasaki S; Shoji Y; Ishida Y; Kinjo T; Tsushima Y; Seno M; Nishizaki F; Itoh T; Izumiyama K; Yokota T; Yokoyama H; Yamada M; Horiuchi D; Kimura M; Higuma T; Tomita H; Okumura K J Cardiol; 2017 Jan; 69(1):359-363. PubMed ID: 27595899 [TBL] [Abstract][Full Text] [Related]
24. Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation. Healy CA; Carrillo RG Heart Rhythm; 2015 Jul; 12(7):1565-73. PubMed ID: 25839113 [TBL] [Abstract][Full Text] [Related]
25. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients. Spar DS; Bianco NR; Knilans TK; Czosek RJ; Anderson JB Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006163. PubMed ID: 29945928 [TBL] [Abstract][Full Text] [Related]
26. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Klein HU; Meltendorf U; Reek S; Smid J; Kuss S; Cygankiewicz I; Jons C; Szymkiewicz S; Buhtz F; Wollbrueck A; Zareba W; Moss AJ Pacing Clin Electrophysiol; 2010 Mar; 33(3):353-67. PubMed ID: 19889186 [TBL] [Abstract][Full Text] [Related]
27. The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know? Barsheshet A; Vamvouris T; Goldenberg I Expert Rev Med Devices; 2016 Jul; 13(7):627-32. PubMed ID: 27333818 [TBL] [Abstract][Full Text] [Related]
28. The wearable cardioverter defibrillator as a bridge to reimplantation in patients with ICD or CRT-D-related infections. Castro L; Pecha S; Linder M; Vogler J; Gosau N; Meyer C; Willems S; Reichenspurner H; Hakmi S J Cardiothorac Surg; 2017 Nov; 12(1):99. PubMed ID: 29178898 [TBL] [Abstract][Full Text] [Related]
30. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
31. The implantable cardioverter defibrillator as a "bridge to transplant": a viable clinical strategy? Schmidinger H Am J Cardiol; 1999 Mar; 83(5B):151D-157D. PubMed ID: 10089858 [TBL] [Abstract][Full Text] [Related]
32. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report. Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888 [TBL] [Abstract][Full Text] [Related]
33. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. Kao AC; Krause SW; Handa R; Karia D; Reyes G; Bianco NR; Szymkiewicz SJ; BMC Cardiovasc Disord; 2012 Dec; 12():123. PubMed ID: 23234574 [TBL] [Abstract][Full Text] [Related]
34. Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. Goldenberg I; Erath JW; Russo AM; Burch AE; Assmus B; Bonderman D; McNitt S; Kutyifa V Heart Rhythm; 2021 Mar; 18(3):404-410. PubMed ID: 33248269 [TBL] [Abstract][Full Text] [Related]
35. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population. Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719 [TBL] [Abstract][Full Text] [Related]
36. Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Veltmann C; Winter S; Duncker D; Jungbauer CG; Wäßnig NK; Geller JC; Erath JW; Goeing O; Perings C; Ulbrich M; Roser M; Husser D; Gansera LS; Soezener K; Malur FM; Block M; Fetsch T; Kutyifa V; Klein HU Clin Res Cardiol; 2021 Jan; 110(1):102-113. PubMed ID: 32377784 [TBL] [Abstract][Full Text] [Related]
37. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]
38. Use of the Wearable Cardioverter Defibrillator in High-Risk Populations. Lamichhane M; Safadi A; Surapaneni P; Salehi N; Thakur RK Curr Cardiol Rep; 2016 Aug; 18(8):78. PubMed ID: 27319008 [TBL] [Abstract][Full Text] [Related]